Molecular Targeted Therapy in Ovarian Cancer: What is on the Horizon?

Hdl Handle:
http://hdl.handle.net/10147/136357
Title:
Molecular Targeted Therapy in Ovarian Cancer: What is on the Horizon?
Authors:
Kalachand, Roshni; Hennessy, Bryan T; Markman, Maurie
Affiliation:
Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland.
Citation:
Molecular Targeted Therapy in Ovarian Cancer: What is on the Horizon? 2011, 71 (8):947-67 Drugs
Journal:
Drugs
Issue Date:
28-May-2011
URI:
http://hdl.handle.net/10147/136357
DOI:
10.2165/11591740-000000000-00000
PubMed ID:
21668036
Additional Links:
http://www.ncbi.nlm.nih.gov/pubmed/21668036
Abstract:
Over the past two decades, empirical optimization of cytotoxic chemotherapy combinations and surgical debulking procedures have improved outcomes and survival in epithelial ovarian cancer. Yet, this disease remains the fifth leading cause of cancer-related deaths in the US, as cure rates seem to have reached a plateau at approximately 20% with conventional chemotherapy. Novel high-throughput genomic and proteomic analyses have improved the molecular understanding of ovarian carcinogenesis, thereby providing a vast array of new potential drug targets with complex signalling interactions. In order to yield the most significant impact on disease outcome, it is necessary to carefully select, and subsequently target, the driving molecular pathway(s) within a tumour or tumour subtype, which are most likely to correspond to high-frequency mutations and genomic aberrations. The identification of biomarkers predictive of response to targeted therapy is essential to avoid poor responses to potentially useful drugs in unselected trial populations. With some promising, albeit early, phase III data on the angiogenesis inhibitor bevacizumab, exciting new opportunities lie ahead with the ultimate goal of personalizing therapies to individual tumour profiles.
Item Type:
Article
Language:
en
ISSN:
0012-6667

Full metadata record

DC FieldValue Language
dc.contributor.authorKalachand, Roshnien
dc.contributor.authorHennessy, Bryan Ten
dc.contributor.authorMarkman, Maurieen
dc.date.accessioned2011-07-19T14:16:47Z-
dc.date.available2011-07-19T14:16:47Z-
dc.date.issued2011-05-28-
dc.identifier.citationMolecular Targeted Therapy in Ovarian Cancer: What is on the Horizon? 2011, 71 (8):947-67 Drugsen
dc.identifier.issn0012-6667-
dc.identifier.pmid21668036-
dc.identifier.doi10.2165/11591740-000000000-00000-
dc.identifier.urihttp://hdl.handle.net/10147/136357-
dc.description.abstractOver the past two decades, empirical optimization of cytotoxic chemotherapy combinations and surgical debulking procedures have improved outcomes and survival in epithelial ovarian cancer. Yet, this disease remains the fifth leading cause of cancer-related deaths in the US, as cure rates seem to have reached a plateau at approximately 20% with conventional chemotherapy. Novel high-throughput genomic and proteomic analyses have improved the molecular understanding of ovarian carcinogenesis, thereby providing a vast array of new potential drug targets with complex signalling interactions. In order to yield the most significant impact on disease outcome, it is necessary to carefully select, and subsequently target, the driving molecular pathway(s) within a tumour or tumour subtype, which are most likely to correspond to high-frequency mutations and genomic aberrations. The identification of biomarkers predictive of response to targeted therapy is essential to avoid poor responses to potentially useful drugs in unselected trial populations. With some promising, albeit early, phase III data on the angiogenesis inhibitor bevacizumab, exciting new opportunities lie ahead with the ultimate goal of personalizing therapies to individual tumour profiles.-
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/21668036en
dc.titleMolecular Targeted Therapy in Ovarian Cancer: What is on the Horizon?en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Beaumont Hospital, Dublin, Ireland.en
dc.identifier.journalDrugsen
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.